Underuse of Effective Cardiac Medications Among Women, Middle-Aged Adults, and Racial/Ethnic Minorities With Coronary Artery Disease (from the National Health and Nutrition Examination Survey 2005 to 2014)
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Authors
Tran, HoangWaring, Molly E.
McManus, David D.
Erskine, Nathaniel
Do, Van T. H.
Kiefe, Catarina I.
Goldberg, Robert J.
UMass Chan Affiliations
Division of Cardiovascular Medicine, Department of MedicineDepartment of Quantitative Health Sciences
Document Type
Journal ArticlePublication Date
2017-10-15
Metadata
Show full item recordAbstract
Given the proven effectiveness of several cardiac medications for patients with coronary artery disease (CAD), we examined the national use of 4 classes of effective medications, overall and by age, sex, and race/ethnicity in 2005 to 2014. We used data from the National Health and Nutrition Examination Survey, including a self-reported diagnosis of CAD and independently verified medication use. Weighting procedures extrapolated our data to the adult US population with CAD. Analyses included 1,789 US adults aged > /=45 years with a history of CAD. The average age of this population was 68 years; 40% were women and 79% were non-Hispanic whites. In 2005 to 2014, 53.2% (standard error [SE] = 1.5) reported use of angiotensin-converting enzyme inhibitor/angiotensin receptor blockers, 58.5% (SE = 1.5) beta blockers, and 67.2% (SE = 1.4) statins. Two of these medications were used by 64.1% (SE = 1.5) of the study population and all 3 by 29.1% (SE = 1.3). In 2011 to 2014, 68.5% (SE = 2.4) of American adults with a history of CAD reported use of aspirin. The use of statins increased from 63.1% in 2005/2006 to 76.8% in 2013/2014. Adults aged 45 to 64 years old, women, and racial/ethnic minorities had lower use of effective cardiac medications compared with older adults, men, and non-Hispanic whites. In conclusion, the use of statins, but not other medications, has increased over the past 10 years among American adults with previously diagnosed CAD. Continued targeted efforts are needed to increase the receipt of effective cardiac medications among all US adults with CAD, especially those aged 45 to 64 years, women, and racial/ethnic minorities.Source
Am J Cardiol. 2017 Oct 15;120(8):1223-1229. doi: 10.1016/j.amjcard.2017.07.004. Epub 2017 Jul 24. Link to article on publisher's siteDOI
10.1016/j.amjcard.2017.07.004Permanent Link to this Item
http://hdl.handle.net/20.500.14038/29155PubMed ID
28822562Related Resources
ae974a485f413a2113503eed53cd6c53
10.1016/j.amjcard.2017.07.004